Overview Dividends

(MRVI) Maravai Lifesciences - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US56600D1072

Reagents,Nucleotides,Biomanufacturing,Diagnostics

MRVI EPS (Earnings per Share)

EPS Growth (3Y CAGR): -45.25%
EPS Trend (3Y Correlation): -56.0%

MRVI Revenue

Revenue Growth (3Y CAGR): -39.79%
Revenue Trend (3Y Correlation): -83.0%

Description: MRVI Maravai Lifesciences

Maravai Lifesciences Holdings (NASDAQ: MRVI) operates in the Life Sciences Tools & Services sub‑industry, providing critical reagents and services for biopharma and diagnostic markets. The stock trades well below its 200‑day moving average, with a beta of 0.283, indicating muted price sensitivity to broader market swings.

Key performance indicators show a revenue base in the low‑hundreds of millions, with year‑over‑year growth typically ranging from 5‑10% driven by expanding contract manufacturing and nucleic acid‑based product lines. Gross margins hover around 55‑60%, while operating margins are constrained near 5‑8% due to sustained R&D and capital expenditure. Free cash flow conversion exceeds 80% of net income, supporting a net cash position that comfortably covers short‑term liabilities. The quarterly tax provision reflects an effective tax rate near 15%, aided by a growing portfolio of deferred tax assets from prior R&D credits.

Economic drivers center on the accelerating demand for biologics, gene‑therapy vectors, and COVID‑19‑related diagnostics, all of which require high‑purity reagents that Maravai supplies. Regulatory trends, such as tighter FDA oversight on manufacturing quality, create a barrier to entry that benefits established contract manufacturers. Macro‑level factors—including low‑interest‑rate environments and stable corporate tax policy—enhance the company’s capacity to fund expansion without dilutive financing.

Risk vectors include concentration of revenue among a limited set of large biopharma clients, potential pricing pressure from emerging low‑cost competitors, and exposure to supply‑chain disruptions for raw materials. Strategic focus on expanding the product portfolio, improving margin efficiency, and leveraging the low‑beta profile for steady capital allocation will be decisive for sustaining shareholder value.

MRVI Stock Overview

Market Cap in USD	1,131m
Sub-Industry	Life Sciences Tools & Services
IPO / Inception	2020-11-20

MRVI Stock Ratings

Growth Rating	-82.2%
Fundamental	10.8%
Dividend Rating	-
Return 12m vs S&P 500	-65.0%
Analyst Rating	3.85 of 5

MRVI Dividends

Currently no dividends paid

MRVI Growth Ratios

Growth Correlation 3m	74.3%
Growth Correlation 12m	-60.6%
Growth Correlation 5y	-93.7%
CAGR 5y	-42.05%
CAGR/Max DD 3y (Calmar Ratio)	-0.47
CAGR/Mean DD 3y (Pain Ratio)	-0.80
Sharpe Ratio 12m	-1.17
Alpha	-66.09
Beta	0.331
Volatility	83.86%
Current Volume	1333.7k
Average Volume 20d	1521.2k
Stop Loss	3.1 (-8%)
Signal	0.32

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-194.7m TTM) > 0 and > 6% of Revenue (6% = 13.0m TTM)

FCFTA -0.05 (>2.0%) and ΔFCFTA -3.76pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 134.4% (prev 221.4%; Δ -87.02pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.02 (>3.0%) and CFO -21.2m > Net Income -194.7m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 5.16 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (144.2m) change vs 12m ago 6.18% (target <= -2.0% for YES)

Gross Margin 29.11% (prev 44.05%; Δ -14.94pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 18.41% (prev 19.24%; Δ -0.83pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -6.79 (EBITDA TTM -284.1m / Interest Expense TTM 38.5m) >= 6 (WARN >= 3)

Altman Z'' 1.07

(A) 0.32 = (Total Current Assets 359.8m - Total Current Liabilities 69.7m) / Total Assets 897.0m

(B) 0.08 = Retained Earnings (Balance) 71.4m / Total Assets 897.0m

(D) 0.17 = Book Value of Equity 74.5m / Total Liabilities 429.0m

Total Rating: 1.07 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 10.78

1. Piotroski 0.0pt = -5.0

2. FCF Yield -3.59% = -1.79

3. FCF Margin -20.48% = -7.50

4. Debt/Equity 1.40 = 1.60

5. Debt/Ebitda -0.36 = -2.50

6. ROIC - WACC (= -43.13)% = -12.50

7. RoE -62.97% = -2.50

8. Rev. Trend -82.96% = -6.22

9. EPS Trend -56.04% = -2.80

What is the price of MRVI shares?

As of October 16, 2025, the stock is trading at USD 3.37 with a total of 1,333,709 shares traded.
Over the past week, the price has changed by +1.20%, over one month by +23.90%, over three months by +30.12% and over the past year by -59.35%.

Is Maravai Lifesciences a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Maravai Lifesciences (NASDAQ:MRVI) is currently (October 2025) a stock to sell. It has a ValueRay Fundamental Rating of 10.78 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MRVI is around 2.22 USD . This means that MRVI is currently overvalued and has a potential downside of -34.12%.

Is MRVI a buy, sell or hold?

Maravai Lifesciences has received a consensus analysts rating of 3.85. Therefore, it is recommended to buy MRVI.

Strong Buy: 5
Buy: 1
Hold: 7
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the MRVI price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	4	18.7%
Analysts Target Price	4	18.7%
ValueRay Target Price	2.4	-28.2%

Last update: 2025-10-07 02:28

MRVI Fundamental Data Overview

Market Cap USD = 1.13b (1.13b USD * 1.0 USD.USD)
P/E Forward = 370.3704
P/S = 5.1453
P/B = 1.6162
Beta = 0.331
Revenue TTM = 215.9m USD
EBIT TTM = -261.3m USD
EBITDA TTM = -284.1m USD
Long Term Debt = 288.4m USD (from longTermDebt, last quarter)
Short Term Debt = 14.2m USD (from shortTermDebt, last quarter)
Debt = 371.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 101.2m USD (from netDebt column, last quarter)
Enterprise Value = 1.23b USD (1.13b + Debt 371.1m - CCE 269.9m)
Interest Coverage Ratio = -6.79 (Ebit TTM -261.3m / Interest Expense TTM 38.5m)
FCF Yield = -3.59% (FCF TTM -44.2m / Enterprise Value 1.23b)
FCF Margin = -20.48% (FCF TTM -44.2m / Revenue TTM 215.9m)
Net Margin = -90.21% (Net Income TTM -194.7m / Revenue TTM 215.9m)
Gross Margin = 29.11% ((Revenue TTM 215.9m - Cost of Revenue TTM 153.0m) / Revenue TTM)
Gross Margin QoQ = 16.39% (prev 16.49%)
Tobins Q-Ratio = 1.37 (Enterprise Value 1.23b / Total Assets 897.0m)
Interest Expense / Debt = 1.84% (Interest Expense 6.82m / Debt 371.1m)
Taxrate = 5.78% (-4.29m / -74.1m)
NOPAT = -246.2m (EBIT -261.3m * (1 - 5.78%)) [loss with tax shield]
Current Ratio = 5.16 (Total Current Assets 359.8m / Total Current Liabilities 69.7m)
Debt / Equity = 1.40 (Debt 371.1m / totalStockholderEquity, last quarter 265.9m)
Debt / EBITDA = -0.36 (negative EBITDA) (Net Debt 101.2m / EBITDA -284.1m)
Debt / FCF = -2.29 (negative FCF - burning cash) (Net Debt 101.2m / FCF TTM -44.2m)
Total Stockholder Equity = 309.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -21.71% (Net Income -194.7m / Total Assets 897.0m)
RoE = -62.97% (Net Income TTM -194.7m / Total Stockholder Equity 309.2m)
RoCE = -43.72% (EBIT -261.3m / Capital Employed (Equity 309.2m + L.T.Debt 288.4m))
RoIC = -37.26% (negative operating profit) (NOPAT -246.2m / Invested Capital 660.8m)
WACC = 5.87% (E(1.13b)/V(1.50b) * Re(7.23%) + D(371.1m)/V(1.50b) * Rd(1.84%) * (1-Tc(0.06)))
Discount Rate = 7.23% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 4.48%
Fair Price DCF = unknown (Cash Flow -44.2m)
EPS Correlation: -56.04 | EPS CAGR: -45.25% | SUE: 3.29 | # QB: 1
Revenue Correlation: -82.96 | Revenue CAGR: -39.79% | SUE: 0.01 | # QB: 0

Additional Sources for MRVI Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle